Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for prevention of hematologic toxicity in neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic cancer
ChiCTR2600128499Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trilaciclib in pancreatic adenocarcinoma (PDAC), sponsored by Huashan Hospital. Primary endpoint: Incidence of neutropenia during neoadjuvant chemotherapy. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600128499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128499.